{"entity":{"id":"golidocitinib","kind":"drug","name":"Golidocitinib","aka":[],"tldr":"Golidocitinib is Dizal's JAK1 inhibitor, approved in China in 2024 as the first JAK inhibitor for relapsed peripheral T-cell lymphoma, a cancer with few options after first-line chemotherapy.","summary":"Dizal Pharmaceutical's golidocitinib (DZD4205) was approved by the NMPA in June 2024 for relapsed or refractory peripheral T-cell lymphoma, on the JACKPOT8 trial in which about 44 percent of patients responded. It is the first JAK1-selective inhibitor approved for a cancer. A phase 3 trial testing it as maintenance after first-line therapy is registered.","status":"approved","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Golidocitinib","url":"https://clinicaltrials.gov/search?intr=DZD4205"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07234162"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, curated)","editedOn":"2026-09-16"},"code":"DZD4205","modality":"Oral selective JAK1 inhibitor","mechanism":"Selectively inhibits Janus kinase 1, the signalling node that peripheral T-cell lymphoma cells use through the JAK-STAT pathway.","approvals":[{"region":"CN","year":2024,"indication":"Relapsed or refractory peripheral T-cell lymphoma"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/golidocitinib/","neighbours":{"cancer":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"trial":[{"id":"nct07234162","kind":"trial","name":"A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)","route":"/trials/nct07234162/"},{"id":"nct07496229","kind":"trial","name":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","route":"/trials/nct07496229/"}]}}